Display options
Cite
Toumi H, Benaitreau D, Pallu S, et al. Effects of anti-sclerostin antibody and running on bone remodeling and strength. Bone Rep. 2015;2:52-58doi: 10.1016/j.bonr.2015.03.002.
Toumi, H., Benaitreau, D., Pallu, S., Mazor, M., Hambli, R., Ominsky, M., & Lespessailles, E. (2015). Effects of anti-sclerostin antibody and running on bone remodeling and strength. Bone reports, 252-58. https://doi.org/10.1016/j.bonr.2015.03.002
Toumi, H, et al. "Effects of anti-sclerostin antibody and running on bone remodeling and strength." Bone reports vol. 2 (2015): 52-58. doi: https://doi.org/10.1016/j.bonr.2015.03.002
Toumi H, Benaitreau D, Pallu S, Mazor M, Hambli R, Ominsky M, Lespessailles E. Effects of anti-sclerostin antibody and running on bone remodeling and strength. Bone Rep. 2015 Apr 11;2:52-58. doi: 10.1016/j.bonr.2015.03.002. eCollection 2015 Jun. PMID: 28377954; PMCID: PMC5365189.
Copy Download .nbib Format: NLM
Share it on

Bone Rep. 2015 Apr 11;2:52-58. doi: 10.1016/j.bonr.2015.03.002. eCollection 2015 Jun.

Effects of anti-sclerostin antibody and running on bone remodeling and strength.

Bone reports

H Toumi, D Benaitreau, S Pallu, M Mazor, R Hambli, M Ominsky, E Lespessailles

Affiliations

  1. Service de Rhumatologie, Centre hospitalier régional d'Orléans, 1 rue Porte Madeleine, 45032 Orléans, France; University of Orléans, I3MTO Laboratory, EA 4708, Hospital of Orleans, 1 rue Porte Madeleine, F-45032 Orléans, France.
  2. University of Orléans, I3MTO Laboratory, EA 4708, Hospital of Orleans, 1 rue Porte Madeleine, F-45032 Orléans, France.
  3. Prisme Institute, MMH, 8, Rue Leonard de Vinci, 45072 Orleans Cedex 2, France.
  4. Metabolic Disorders, Amgen Inc., One Amgen Center Dr., Thousand Oaks, 91320 CA, USA.

PMID: 28377954 PMCID: PMC5365189 DOI: 10.1016/j.bonr.2015.03.002

Abstract

Sclerostin antibody (Scl-Ab) represents a promising therapeutic approach to treat patients with osteoporosis.

PURPOSE: The aim of this study was to investigate the effects of Scl-Ab, running and a combination of both on bone formation.

METHODS: Sixty female Wistar rats, aged 8 months were randomly assigned to five groups (subcutaneous injections performed twice a week): (1) (Sham): sedentary rats + saline, (2) (OVX): ovariectomized rats + saline, (3) (OVX + E): OVX rats + saline + treadmill training (5 times/week, 1 h/day), (4) (OVX + E + S): OVX rats + treadmill training + 5 mg/kg Scl-Ab and (5) (OVX + S): OVX rats + 5 mg/kg Scl-Ab. After 14 weeks, body composition, whole body and femoral BMDs were determined by DXA and serum was collected for analysis of osteocalcin and NTX. Bone microarchitecture was analyzed using μCT and bone strength was assessed at the femur mid-shaft in 3-point bending.

RESULTS: Running exercise decreased fat mass as well as the bone resorption marker NTX relative to the non-exercised control groups, effects that were associated with a prevention of the deleterious effects of OVX on whole body and femoral BMDs. Scl-Ab increased the bone formation marker osteocalcin, which resulted in robust increases in BMD and femoral metaphyseal bone volume to levels greater than in the Sham group. OVX + S + E group did not further impact on bone mass relative to the OVX + S group. At the cortical femur diaphysis, Scl-Ab prevented the decreases in bone strength after OVX, while exercise did not affect cortical strength.

CONCLUSION: We suggest that while running on a treadmill can prevent some bone loss through a modest antiresorptive effect, it did not contribute to the robust bone-forming effects of Scl-Ab when combined in an estrogen ablation model.

Keywords: Anti-sclerostin antibody; Osteocyte; Osteoporosis; Physical exercise

References

  1. J Med Assoc Thai. 2011 Oct;94 Suppl 5:S17-23 - PubMed
  2. Endocr Rev. 2012 Oct;33(5):747-83 - PubMed
  3. J Bone Miner Res. 2008 Jun;23 (6):860-9 - PubMed
  4. J Bone Miner Res. 2009 Apr;24(4):578-88 - PubMed
  5. J Bone Joint Surg Br. 2000 May;82(4):591-4 - PubMed
  6. Osteoporos Int. 2008 May;19(5):595-606 - PubMed
  7. J Med Assoc Thai. 2009 Sep;92 Suppl5:S102-8 - PubMed
  8. J Clin Endocrinol Metab. 2013 Feb;98(2):592-601 - PubMed
  9. Bone Miner. 1994 Aug;26(2):133-40 - PubMed
  10. J Biol Chem. 2008 Feb 29;283(9):5866-75 - PubMed
  11. J Bone Miner Res. 2013 Jul;28(7):1599-610 - PubMed
  12. J Orthop Surg Res. 2011 Jun 15;6:30 - PubMed
  13. J Bone Miner Metab. 2004;22(5):500-8 - PubMed
  14. Bone. 1993 Jul-Aug;14(4):595-608 - PubMed
  15. J Bone Miner Res. 1993 Aug;8(8):937-42 - PubMed
  16. Acta Orthop. 2011 Oct;82(5):628-32 - PubMed
  17. J Appl Physiol (1985). 2003 Sep;95(3):1032-7 - PubMed
  18. Spine (Phila Pa 1976). 2013 Apr 15;38(8):E487-92 - PubMed
  19. Eur J Clin Invest. 2012 Dec;42(12):1332-41 - PubMed
  20. PLoS One. 2012;7(6):e40143 - PubMed
  21. Exp Anim. 2005 Jan;54(1):1-6 - PubMed
  22. Biol Res. 2012;45(2):163-9 - PubMed
  23. Bone. 2011 Feb;48(2):197-201 - PubMed
  24. Am J Phys Anthropol. 2012 Apr;147(4):618-28 - PubMed
  25. J Bone Miner Res. 1997 Oct;12(10):1539-46 - PubMed
  26. Proc Natl Acad Sci U S A. 2012 Feb 28;109 (9):3359-64 - PubMed
  27. J Pharmacol Exp Ther. 2006 Sep;318(3):1118-27 - PubMed
  28. J Strength Cond Res. 2013 Oct;27(10):2879-86 - PubMed
  29. Int J Sports Med. 1997 May;18(4):247-51 - PubMed
  30. Tohoku J Exp Med. 2009 Oct;219(2):139-43 - PubMed
  31. Calcif Tissue Int. 1997 May;60(5):441-8 - PubMed
  32. Clin Interv Aging. 2007;2(1):55-64 - PubMed
  33. Endocr Metab Immune Disord Drug Targets. 2009 Dec;9(4):371-84 - PubMed
  34. J Anat. 2012 Jun;220(6):632-7 - PubMed
  35. Curr Opin Rheumatol. 2012 Sep;24(5):561-6 - PubMed
  36. Swiss Med Wkly. 2012 Jul 19;142:w13624 - PubMed
  37. J Bone Miner Res. 2009 Oct;24(10):1651-61 - PubMed
  38. FASEB J. 2005 Nov;19(13):1842-4 - PubMed
  39. N Engl J Med. 2014 Jan 30;370(5):412-20 - PubMed
  40. J Bone Miner Metab. 2004;22(1):26-31 - PubMed
  41. J Bone Miner Res. 1994 Oct;9(10):1559-64 - PubMed
  42. J Bone Miner Res. 2011 Feb;26(2):229-38 - PubMed

Publication Types